Cell Biology

Clarification: A version of Stephen J. Elledge's comment on this paper, which appeared in the Sept. 14, 1992, issue of The Scientist, contained an editing error that significantly altered its meaning. Following is a corrected version of Elledge's remarks. S.J. Elledge and M.R. Spottswood, "A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces-cerevisiae, is a homolog of Xenopus Eg1," The EMBO Journal, 10:2653-9, 1991. Stephen J. Elledge (Ba

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Clarification: A version of Stephen J. Elledge's comment on this paper, which appeared in the Sept. 14, 1992, issue of The Scientist, contained an editing error that significantly altered its meaning. Following is a corrected version of Elledge's remarks.

S.J. Elledge and M.R. Spottswood, "A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces-cerevisiae, is a homolog of Xenopus Eg1," The EMBO Journal, 10:2653-9, 1991.

Stephen J. Elledge (Baylor College of Medicine, Houston): "Critical transitions in the eukaryotic cell cycle are controlled by the activity and substrate specificity of a protein kinase, p34cdc2, and its associated regulatory subunits, cyclins. In yeasts, this kinase is encoded by a single gene and is capable of regulating entry into two very different cellular states: S-phase (DNA synthesis) and M-phase (mitosis). Prior to this work, it was thought that human cells also possessed only a single CDC2-like gene, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies